Q2 2025 Evogene Ltd Earnings Call

Speaker #1: Welcome to Evogene's second quarter 2025 results conference call. All participants are present in listen-only mode. Following management's formal presentation, we will open the question and answer session.

Speaker #1: You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded August 19th, 2025.

Speaker #1: Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events.

Speaker #1: This presentation contains forward-looking statements relating to future events and Evogene Ltd. The company may from time to time make other statements regarding our outlook.

Speaker #1: Or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the U.S.

Speaker #1: Private Securities Litigation Reform Act of 1995, the PSLRA, and other securities laws, as amended, state that statements that are not statements of historical fact may be deemed to be forward-looking statements.

Speaker #1: Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend," and "potential," or words of similar meaning.

Speaker #1: We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts, and timing. Product development and launches, estimated market sizes and milestones, pipelines, as well as our capabilities and technology.

Speaker #1: Such statements are based on current expectations, estimates, projections, and assumptions. They describe opinions about future events and involve certain risks and uncertainties, which are difficult to predict and are not guarantees of future performance.

Speaker #1: Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statements.

Speaker #1: That may be made in this presentation. Therefore, actual future results, performance, or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements.

Speaker #1: Due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel, Hamas, and Hezbollah, and any worsening of the situation in Israel.

Speaker #1: Such as further mobilizations or escalation in the northern border of Israel, those described in greater detail in Evogene's annual report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S.

Speaker #1: Securities and Exchange Commission. Including those factors under the heading "Risk Factors," except as required by applicable securities laws. We disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events, developments, or changes in expectations, estimates, projections, and assumptions.

Speaker #1: The information contained herein does not constitute a prospectus or other offering document. Nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation to offer, purchase, or subscribe for any securities of Evogene or the company. Nor shall the information, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with, any action, contract, commitment, or relating thereto, or to the securities of Evogene or the company.

Speaker #1: The trademarks included herein are the property of their respective owners and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Speaker #1: With us on the line will be Ofer Haviv, President and CEO of Evogene, and Yaron Eldad, CFO of Evogene. Now, I will turn the call over to Ofer Haviv.

Speaker #1: Mr. Haviv, please go ahead.

Speaker #2: Hello, everyone. Thank you for joining Evogene's second quarter 2025 analyst call. Today, I will provide an overview of significant developments during the second quarter and through August, resulting from the strategic transition we announced earlier this year.

Speaker #2: I will also share our outlook for the remainder of the year. Following my remarks, our CFO, Yaron Eldad, will present the financial results, and we will then open the call for questions.

Speaker #2: I will start with the financial highlights. In reviewing our financial results for the first half of 2025, it's important to note that Laviv Bio, Evogene's subsidiary, and MicroBoost AI for ad operations are presented as a single line item in the consolidated profit and loss statements.

Speaker #2: This appears under the line titled "Loss from Operations Hold for Sale Net." This accounting treatment follows the intention to sell the majority of Laviv Bio's activity and the MicroBoost AI for Ads as of June 30, 2025.

Speaker #2: Moving to revenue performance, total revenues for the first half of 2025 were approximately $3.2 million, compared to $2.3 million in the first half of 2024.

Speaker #2: This increase was primarily driven by strong seed sales from our subsidiary, Kastera. In addition, during the first half of the year, Evogene initiated and executed a cost reduction plan; most of this plan was completed by the end of the second quarter.

Speaker #2: While the financial impact is partially reflected in our first-half results, we expect to see the full benefit of this reduction in the second half of 2025.

Speaker #2: Turning to our operating expenses, research and development expenses for the first half of 2025 were approximately $4.8 million, compared to approximately $6.5 million in the same period last year.

Speaker #2: This decrease is primarily due to a reduction in R&D activities at Biomica and the discontinuation of operations at Canonic. Sales and marketing expenses totaled approximately $8,000 in the first half of 2025, down from approximately $1.1 million in the first half of 2024.

Speaker #2: The reduction reflects lower headcounts across several of our subsidiaries. Overall, total operating expenses net for the first half of 2025 were approximately $7.7 million, compared to approximately $11.1 million in the same period last year.

Speaker #2: This significant decrease is mainly attributed to the reduced level of activity in our subsidiaries. As of the end of the first half of 2025, Evogen's cash and short-term bank deposits stood at approximately $11.7 million. It is important to note that this cash balance does not include the expected proceeds from the sales of Laviv Bio's assets and the MicroBoost AI for Ad Tech engines to ICL.

Speaker #2: This transaction was completed during the third quarter of 2025. Evogene is currently undergoing a strategic shift focused on maximizing the value of Campus AI, our proprietary platform for AI-driven discovery and optimization of small molecules in both the pharmaceutical and agriculture industries.

Speaker #2: As we shared earlier this year, our strategic priorities include strengthening Campus AI as a core asset, expanding collaboration efforts in small molecule drug discovery, integrating Adama, our subsidiary focused on crop protection product development based on small molecules, into Evogene, and expanding its business collaborations.

Moderator: Welcome to Evogene Ltd.'s second quarter 2025 results conference call. All participants are present in listen-only mode. Following management's formal presentation, we will open the question and answer session. You may send questions via chat. Please type your name and company before your question. As a reminder, this conference is being recorded on August 19, 2025. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene Ltd.'s management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events. Evogene Ltd., the company, may from time to time make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995, the PSLRA, and other securities laws as amended.

Moderator: Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, planned, estimated, intend, and potential, or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts, and timing, product development and launches, estimated market sizes and milestones, pipelines, as well as our capabilities and technology. Such statements are based on current expectations, estimates, projections, and assumptions. Described opinions about future events involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the company's actual results and could cause such results to differ materially from any forward-looking statement that may be made in this presentation.

Moderator: Therefore, actual future results, performance, or achievements and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including without limitation, the current war between Israel, Hamas, and Hezbollah, and any worsening of the situation in Israel, such as further mobilizations or escalation in the northern border of Israel, those described in greater detail in Evogene Ltd.'s annual report on Form 20F and in other information Evogene Ltd. files and furnishes with the Israel Securities Authorities and the U.S. Securities and Exchange Commission, including those factors under the heading Risk Factors.

Moderator: Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections, and assumptions. The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell or any solicitation of any invitation to offer or purchase or subscribe for any securities of Evogene Ltd. or the company, nor shall the information or any part of it or the fact of its distribution form the basis of or be relied on in connection with any action, contract, commitment, or relating thereto or to the securities of Evogene Ltd. or the company.

Moderator: The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services. With us on the line will be Ofer Haviv, President and CEO of Evogene Ltd., and Yaron Eldad, CFO of Evogene Ltd. Now I will turn the call over to Ofer Haviv. Mr. Haviv, please go ahead.

Ofer Haviv: Hello, everyone. Thank you for joining Evogene's second quarter 2025 analyst call. Today, I will provide an overview of significant developments during the second quarter and through August, resulting from the strategic transition we announced earlier this year. I will also share our outlook for the remainder of the year. Following my remarks, our CFO, Yaron Eldad, will present the financial results, and we will then open the call for questions. I will start with the financial highlights. In reviewing our financial results for the first half of 2025, it's important to note that Lavie Bio, Evogene's subsidiary, and MicroBoost AI for ad operations are presented as a single line item in the consolidated profit and loss statement. This appears under the line titled Loss from Operations Hold for Sale Net.

Ofer Haviv: This accounting treatment follows the intention to sell the majority of Lavie Bio's activity and the MicroBoost AI for ad as of June 30, 2025. Moving to revenue performance, total revenues for the first half of 2025 were approximately $3.2 million compared to $2.3 million in the first half of 2024. This increase was primarily driven by a strong seed sale from our subsidiary, Casterra. In addition, during the first half of the year, Evogene initiated and executed a cost reduction plan. Most of this plan was completed by the end of the second quarter. While the financial impact is partially reflected in our first half results, we expect to see the full benefit of these reductions in the second half of 2025.

Ofer Haviv: Turning to our operation expenses, research and development expenses for the first half of 2025 were approximately $4.8 million compared to approximately $6.5 million in the same period last year. This decrease is primarily due to a reduction in R&D activities at Biomica and the discontinuation of operation at Canonic. Sales and marketing expenses totaled approximately $800,000 in the first half of 2025, down from approximately $1.1 million in the first half of 2024. The reduction reflects lower headcounts across several of our subsidiaries. Overall, total operating expenses net for the first half of 2025 were approximately $7.7 million compared to approximately $11.1 million in the same period last year. This significant decrease is mainly attributed to the reduced level of activity in our subsidiaries. As of the end of the first half of 2025, Evogene's cash and short-term bank deposit stood at approximately $11.7 million.

Ofer Haviv: It is important to note that this cash balance does not include the expected proceeds from the sales of Lavie Bio's assets and the MicroBoost AI for ag-tech engines to ICL. This transaction was completed during the third quarter of 2025. Evogene Ltd. is currently undergoing a strategic shift focused on maximizing the value of Kempas AI, our proprietary platform for AI-driven discovery and optimization of small molecules in both the pharmaceutical and agriculture industries. As we shared earlier this year, our strategic priorities include strengthening Kempas AI as core asset, expanding collaboration efforts in small molecule drug discovery, integrating AgPlenus, our subsidiary focused on crop protection product development based on small molecules, into Evogene Ltd. and expanding its business collaborations, enhancing cash flow primarily from our subsidiaries, and streamlining operational expenses across Evogene Ltd. and its subsidiaries.

Speaker #2: Enhancing cash flow, primarily from our subsidiaries, and streamlining operational expenses across Evogene and its subsidiaries, we executed several impactful actions aligned with this strategy during the second quarter and through August.

Ofer Haviv: We executed several impactful actions aligned with this strategy during the second quarter and through August. With respect to the strengthening our Kempas AI, in June, we announced the completion of version one of our first-in-class generative AI foundation model for small molecule design developed in collaboration with Google Cloud. This model significantly enhanced Kempas AI's capability by addressing a major challenge across pharma and ag-tech, the identification of novel molecules meeting multiple complex criteria. Trained on a proprietary dataset of approximately 38 billion molecular structures and deployed on Google's advanced AI infrastructure, this model lays the groundwork for continued technological leadership and future product development.

Speaker #2: We expect to strengthen our Campus AI in June. We announced the completion of version one of our first-in-class generative AI foundation model for small molecule design, developed in collaboration with Google Cloud.

Speaker #2: This model significantly enhanced Campus AI's capability by addressing a major challenge across pharma and ad tech: the identification of novel molecules meeting multiple complex criteria.

Speaker #2: Trained on a proprietary dataset of approximately 38 billion molecular structures and deployed on Google's advanced AI infrastructure, this model lays the groundwork for continued technological leadership and future product development.

Speaker #2: As part of our efforts for collaboration in pharma, last week we announced a collaboration with Professor Ehud Gazit from Tel Aviv University, a global expert in biomolecular self-assembly, to develop small molecule therapeutics targeting diseases caused by the accumulation of metabolites such as gout and PKU.

Ofer Haviv: As part of our efforts for collaboration in pharma, last week we announced a collaboration with Professor Ehud Gazit from Tel Aviv University, a global expert in biomolecular cell assembly, to develop a small molecule therapeutics targeting disease caused by the accumulation of metabolites such as gout and PKU. This collaboration leverages Kempas AI to identify novel compounds that inhibit the self-assembly of metabolites, a promising and largely untapped therapeutics area. To align our operation with the new strategic direction and as part of the integration of AgPlenus activity into Evogene Ltd., we implemented significant organizational change, including a reduction of over 40% in headcount at AgPlenus. We expect this change to allow for a more effective use of Kempas AI to enhance AgPlenus' pipeline. The most important event that took place since our last analyst call was a transaction with ICL that significantly enhanced our cash flow.

Speaker #2: This collaboration leverages Campus AI to identify novel compounds that inhibit the self-assembly of metabolites by promising and largely untapped therapeutic areas. To align our operations with the new strategic direction and as part of the integration of ad planus activity into Evogene, we implemented significant organizational changes.

Speaker #2: Including a reduction of over 40% in headcount at Ad Planus. We expect this change to allow for a more effective use of Campus AI to enhance the Ad Planus pipeline.

Speaker #2: The most important event that took place since our last analyst call was the transaction with ICL that significantly enhanced our cash flow. In April, we announced the sale of most of Laviv Bio's activity to ICL for a total configuration of $15.25 million. In addition, the Evogen MicroBoost AI platform for agriculture was sold to ICL for $3.5 million.

Ofer Haviv: In April, we announced the sale of most of Lavie Bio's activity to ICL for a total consideration of $15.25 million. In addition, Evogene's MicroBoost AI platform for agriculture was sold to ICL for $3.5 million. As part of the transaction, Lavie Bio redeemed the SAFE investment which was made by an ICL affiliate. This transaction was completed in July and generated cash for Evogene, both directly through the sale of MicroBoost AI and indirectly through dividends, as Evogene remains a major shareholder in Lavie Bio and preserves the upside from a continuing collaboration agreement between Lavie Bio and one of its existing partners, which is excluded from the transaction. As I stated, our strategic priorities included streamlining operational expenses across Evogene and its subsidiaries. I would like to share with you the steps taken in Biomica and Evogene.

Speaker #2: As part of the transaction, Laviv Bio redeemed the SAFE investment, which was made by an ICL affiliate. This transaction was completed in July and generated cash for Evogene both directly through the sale of MicroBoost AI for Ad and indirectly through dividends, as Evogene remains a major shareholder in Laviv Bio and preserves the upside from a continuing collaboration agreement between Laviv Bio and one of its existing partners, which is excluded from the transaction.

Speaker #2: As I stated, our strategic priorities include streamlining operational expenses across Evogene and its subsidiaries. I would like to share with you the steps taken in Biomica and Evogene.

Speaker #2: In the second quarter, we began a streamlining process at Biomica, which included a significant workforce reduction and organizational change at the management level. During this time, Mr. Elham Heber, CEO of Biomica, stepped down from his role due to health reasons.

Ofer Haviv: In the second quarter, we began a streamlining process at Biomica, which included a significant workforce reduction and organizational change at the management level. During this time, Mr. Elram Hever, CEO of Biomica, stepped down from his role due to health reasons. We extend our best wishes for his full and speedy recovery. In the interim, I have assumed direct responsibility for overseeing Biomica's operations. Biomica is now focused on two key goals: completion of its clinical trial expected in early 2026 and securing partners to take the lead on its development programs. As of now, Biomica holds approximately $4 million in cash, enough to complete the clinical trial. We will share more updates as progress continues. With respect to Evogene, to support our new strategic focus, we implemented major organizational restructuring, which included workforce reduction of approximately 30%.

Speaker #2: We extend our best wishes for his full and speedy recovery. In the interim, I have assumed direct responsibility for overseeing Biomica's operations. Biomica is now focused on two key goals.

Speaker #2: Completion of its clinical trial, expected in early 2026, and securing partners to take the lead on its development programs. As of now, Biomica holds approximately $4 million in cash, enough to complete the clinical trial.

Speaker #2: We will share more updates as progress continues. We expect Evogene to support our new strategic focus; we implemented major organizational restructuring, which included a workforce reduction of approximately 30%.

Speaker #2: As stated, the effect of this organizational streamlining will be reflected in our financial report starting in the third quarter of 2025. In addition to this impactful action, we succeeded in strengthening the company's financial position by offering new shares, supporting our ability to implement our strategy over time.

Ofer Haviv: As stated, the effect of this organizational streamlining will be reflected in our financial report starting the third quarter of 2025. In addition to this impactful action, we succeeded in strengthening the company's financial position by offering new shares, supporting our ability to implement our strategy over time. In June, we successfully raised $4.4 million through our at-the-market facility with Lakeside Capital Market at an average price of approximately $2.31 per share based on our shelf registration. We have no further capacity under this ATM facility. The offer met with strong investor interest, signaling confidence in our strategic direction. Combined with the Lavie Bio transaction I have already described, we now have a solid financial foundation and operational runway of approximately 18 months. Let me now outline our expectation for the remainder of 2025.

Speaker #2: In June, we successfully raised $4.4 million through our at-the-market facility with Lextree Capital Market at an average price of approximately $2.31 per share based on our shelf registration.

Speaker #2: We have no further capacity under this ATM facility. The offer met with strong investor interest, signaling confidence in our strategic direction. Combined with the Laviv Bio transaction I have already described, we now have a solid financial foundation and operational runway of approximately 18 months.

Speaker #2: Let me now outline our expectations for the remainder of 2025. As stated earlier, our new strategy centers around a single computational engine, our Campus AI platform, for accelerating small molecule-based innovation.

Speaker #2: Our primary target is to continue investing in the unique offering of our engines' cutting edge. To maintain our competitive edge, we intend to continue advancing our technology, including partnerships with global tech leaders such as Google, and leveraging our platform performance to new heights.

Ofer Haviv: As stated earlier, our new strategy centers around a single computational engine, our Kempas AI platform for accelerating small molecule-based innovation. Our primary target is to continue investing in the unique offering of our engine's cutting edge. To maintain our competitive edge, we intend to continue advancing our technology, including partnerships with global tech leaders such as Google Cloud, aimed at elevating our platform performance to new heights. We intend for this platform to serve two key verticals: pharma for the discovery and optimization of small molecules therapeutics; agriculture for the development of crop protection products. With respect to the pharma vertical, the collaboration engagement with Tel Aviv University is part of a broader plan to establish Evogene's partner ecosystem in pharma across academic and industry, in Israel and internationally. This is the first of several such initiatives we are currently advancing.

Speaker #2: We intend for this platform to serve two key verticals: pharma for the discovery and optimization of small molecules and therapeutics, and agriculture for the development of crop protection products.

Speaker #2: With respect to the pharma vertical, the collaboration engagement with Tel Aviv University is part of a broader plan to establish Evogene's partner ecosystem in pharma.

Speaker #2: Across academic and industry, in Israel and internationally, this is the first of several such initiatives we are currently advancing. We will establish a dedicated business development arm led by a senior executive to accelerate growth in the pharma vertical.

Speaker #2: In agriculture, we will continue to operate through Adama, which maintained strategic collaboration with Bayer and Corteva. We anticipate further growth in this area, including new partnerships later this year.

Ofer Haviv: We will establish a dedicated business development arm led by a Senior Executive to accelerate growth in the pharma vertical. In agriculture, we will continue to operate through AgPlenus, which maintains strategic collaboration with Bayer and Corteva. We anticipate further growth in this area, including new partnerships later this year with both existing and new partners. Now, let's continue with our expectation for our other subsidiaries in line with our strategic focus: Lavie Bio. Following the sale of the majority of the company's activity, Lavie Bio will maintain only its existing collaboration agreement with its existing partner and is expected to distribute funds to its shareholders with Evogene as the majority holder. No additional activity is expected. Biomica is expected to complete its clinical trial in early 2026 and continue efforts to secure partners to lead its current development programs. No additional activities are expected.

Speaker #2: With both existing and new partners, let's continue with our expectations for our other subsidiaries in line with our strategic focus. Laviv Bio, following the sale of the majority of the company's activity, will maintain only its existing collaboration agreement with current partners and is expected to distribute funds to its shareholders, with Evogen as the majority holder.

Speaker #2: No additional activity is expected. Biomica is anticipated to complete its clinical trial in early 2026 and continue efforts to secure partners to lead its current development programs.

Speaker #2: No additional activities are expected. Our plans for Kastera, our wholly owned subsidiary offering an integrated solution for growing castor as a feedstock, differ from our other subsidiaries.

Speaker #2: Even though it's not directly tied to our strategy and core technology, we intend to continue supporting the company's activity in the future. Over the past few months, Kastera has begun entering new markets and marketing channels, and we see strong potential in its operations to build a sustainable revenue stream.

Ofer Haviv: Our plans for Casterra, our wholly owned subsidiary, offering an integrated solution for growing cash flow as a feedstock, differ from our other subsidiaries. Even though it is not directly tied to our strategy and core technology, we intend to continue supporting the company's activity in the future. Over the past few months, Casterra has begun entering new markets and marketing channels, and we see strong potential in its operations to build a sustainable revenue stream. The company is advancing multiple business initiatives, and we will update you as these develop. In summary, we are progressing steadily with the execution of our new strategy. The steps taken this quarter reflect a clear commitment to focus operational discipline and long-term value creation. Beginning in September, I will have the honor of presenting Evogene's updated corporate strategy at selected industry conferences and professional events.

Speaker #2: The company is advancing multiple business initiatives, and we will update you as these develop. In summary, we are progressing steadily with the execution of our new strategy.

Speaker #2: The steps taken this quarter reflect a clear commitment to focus on operational discipline and long-term value creation. Beginning in September, I will have the honor of presenting Evogene's updated corporate strategy at selected industry conferences and professional events.

Speaker #2: I encourage you to follow our official publications for updates, and I would welcome the opportunity to connect with you at these engagements. We will continue to keep our shareholders, partners, and analysts informed as we advance toward our goals.

Ofer Haviv: I encourage you to follow our official publications for updates, and I would welcome the opportunity to connect with you at these engagements. We will continue to keep you, our shareholders, partners, and analysts informed as we advance toward our goals. Thank you for your continued support. Yaron Eldad, Evogene CFO, will now present our financial results for the second quarter. Thank you.

Speaker #2: Thank you for your continued support. Yaron Eldad, Evogene CFO, will now present our financial results for the second quarter. Thank you.

Speaker #3: Thank you, Ofer! As of June 30, 2025, Evogene has consolidated cash, cash equivalents, and short-term bank deposits of approximately $11.7 million. The consolidated cash usage during the second quarter of 2025 was approximately $2.4 million.

Yaron Eldad: Thank you, Ofer Haviv. As of June 30, 2025, Evogene Ltd. had held consolidated cash, cash equivalents, and short-term bank deposits of approximately $11.7 million. The consolidated cash usage during the second quarter of 2025 was approximately $2.4 million. Excluding Lavie Bio and Biomica, Evogene Ltd. and its other subsidiaries used approximately $1 million in cash during the second quarter of 2025. Revenues for the first half of 2025 were approximately $3.2 million compared to approximately $2.2 million in the same period the previous year, reflecting an increase of approximately $0.9 million. This increase was primarily driven by higher revenues recognized by Casterra, attributed to seed sales in the first half of 2025, partially offset by a decrease in AgPlenus revenues, mainly due to revenues from a licensing agreement with Bayer recognized in 2024.

Speaker #3: Excluding Laviv Bio and Biomica, Evogen and its other subsidiaries used approximately $1 million in cash during the second quarter of 2025. Revenues for the first half of 2025 were approximately $3.2 million, compared to approximately $2.3 million in the same period the previous year, reflecting an increase of approximately $0.9 million.

Speaker #3: This increase was primarily driven by higher revenues recognized by Kastera attributed to seed sales in the first half of 2025, partially offset by a decrease in ad planus revenues, mainly due to revenues from a licensing agreement with Bayer recognized in 2024.

Speaker #3: Revenues for the second quarter of 2025 were approximately $0.9 million, a slight increase compared to approximately $0.6 million in the same period last year.

Speaker #3: Research and development expenses net of non-refundable grants for the first half of 2025 were approximately $4.8 million, a decrease of approximately $1.7 million compared to $6.5 million in the first half of 2024.

Yaron Eldad: Revenues for the second quarter of 2025 were approximately $0.9 million, a slight increase compared to approximately $0.6 million in the same period last year. Research and development expenses, net of non-refundable grants, for the first half of 2025 were approximately $4.8 million, a decrease of approximately $1.7 million compared to $6.5 million in the first half of 2024. The decrease was primarily due to reduced R&D expenses in Biomica and the cessation of Canonic's operation at the beginning of 2024. In the second quarter of 2025, R&D expenses were approximately $2.3 million, down from $2.9 million in the same period of 2024. This decrease is mainly attributable to the decreased expenses in Biomica and Casterra. Sales and marketing expenses for the first half of 2025 were approximately $0.8 million, a decrease of approximately $0.3 million compared to approximately $1.1 million in the same period last year.

Speaker #3: The decrease was primarily due to reduced R&D expenses in Biomica and the cessation of Canonic's operations at the beginning of 2024. In the second quarter of 2025, R&D expenses were approximately $2.3 million, down from $2.9 million in the same period of 2024.

Speaker #3: This decrease is mainly attributable to the decreased expenses in Biomica and Kastera. Still, the marketing expenses for the first half of 2025 were approximately $0.8 million, a decrease of approximately $0.3 million compared to approximately $1.1 million in the same period last year.

Speaker #3: The decrease was mainly due to reductions in Evogene, Adagrasib, and Biomica's personnel costs. Still, the marketing expenses for the second quarter of 2025 were approximately $0.4 million, reflecting a decrease of approximately $0.2 million compared to approximately $0.6 million in the second quarter of 2024.

Yaron Eldad: The decrease was mainly due to reductions in Evogene Ltd., AgPlenus, and Biomica's personnel costs. Sales and marketing expenses for the second quarter of 2025 were approximately $0.4 million, reflecting a decrease of approximately $0.2 million compared to approximately $0.6 million in the second quarter of 2024. The decrease was mainly attributable to reduced expenses in Evogene Ltd., Biomica, and AgPlenus, as mentioned above. General and administrative expenses for the first half of 2025 decreased to approximately $2.3 million from approximately $2.9 million in the same period last year. The decrease is mainly attributable to lower personnel costs in Evogene Ltd., a decrease in D&O insurance costs, and lower non-cash compensation expenses in Casterra, Biomica, and AgPlenus.

Speaker #3: The decrease was mainly attributable to reduced expenses in Evogene, Biomica, and Adiplanus, as mentioned above. General and administrative expenses for the first half of 2025 decreased to approximately $2.3 million, down approximately $2.9 million from the same period last year.

Speaker #3: The decrease is mainly attributable to lower personnel costs in Evogene, a decrease in D&O insurance costs, and lower non-cash compensation expenses in Kastera, Biomica, and Adigen. General and administrative expenses for the second quarter of 2025 decreased to approximately $1.1 million, compared to approximately $1.4 million in the same period of the previous year, mainly due to decreased expenses in Evogene as mentioned above.

Speaker #3: Other income of approximately $191 thousand was recorded in the first quarter of 2025, as part of the accounting treatment related to a sublease agreement.

Yaron Eldad: General and administrative expenses for the second quarter of 2025 decreased to approximately $1.1 million compared to approximately $1.4 million in the same period of the previous year, mainly due to decreased expenses in Evogene Ltd., as mentioned above. Other income of approximately $191,000 was recorded in the first quarter of 2025 as part of accounting treatment related to a sublease agreement. The decision to cease Canonic's operation in the first half of 2024 resulted in other expenses of approximately $0.5 million, primarily due to the impairment of fixed assets recorded in the first quarter of 2024. The operating loss for the first half of 2025 was approximately $6.1 million, a significant decrease from approximately $9.4 million in the same period of the previous year, mainly due to decreased operating expenses, as mentioned above.

Speaker #3: The decision to cease Canonic's operation in the first half of 2024 resulted in other expenses of approximately $0.5 million, primarily due to the impairment of fixed assets recorded in the first quarter of 2024.

Speaker #3: The operating loss for the first half of 2025 was approximately $6.1 million, a significant decrease from approximately $9.4 million in the same period of the previous year, mainly due to decreased operating expenses, as mentioned above.

Speaker #3: The operating loss for the second quarter of 2025 was approximately $3.1 million, a decrease from $4.6 million in the same period of the previous year, mainly due to decreased operating expenses, as mentioned above.

Speaker #3: Financing income net for the first half of 2025 was $732 thousand, compared to financing income net of $373 thousand in the same period of the previous year.

Yaron Eldad: The operating loss for the second quarter of 2025 was approximately $3.1 million, a decrease from $4.6 million in the same period of the previous year, mainly due to decreased operating expenses, as mentioned above. Financing income net for the first half of 2025 was $732,000 compared to financing income net of $373,000 in the same period of the previous year. The increase is mainly associated with accounting treatment of pre-funded warrants and warrants issued in August 2024 fundraising. As a result, during the first half of 2025, the company recorded net financial income related to pre-funded warrants and warrants of approximately $663,000. Financing expenses net for the second quarter of 2025 were $393,000 compared to financing income net of $97,000 in the same period of the previous year. The decrease is mainly associated with accounting treatment of pre-funded warrants and warrants issued in August 2024 fundraising.

Speaker #3: The increase is mainly associated with the accounting treatment of pre-funded warrants and warrants issued in the August 2024 fundraising. As a result, during the first half of 2025, the company recorded net financial income related to pre-funded warrants and warrants of approximately $663 thousand.

Speaker #3: Financing expenses, net for the second quarter of 2025, were $393 thousand, compared to financing income, net of $97 thousand in the same period of the previous year.

Speaker #3: The decrease is mainly associated with the accounting treatment of pre-funded warrants and warrants issued in the August 2024 fundraising. Loss from operations held for sale, net for the first half of 2025, was approximately $2.2 million, compared to approximately $0.8 million in the same period of 2024.

Speaker #3: For the second quarter of 2025, the loss from operations held for sale net was approximately $1.2 million, compared to approximately $1.4 million in the second quarter of the previous year.

Yaron Eldad: Loss from operations held for sale net for the first half of 2025 was approximately $2.2 million compared to approximately $0.8 million in the same period of 2024. For the second quarter of 2025, the loss from operations held for sale net was approximately $1.2 million compared to approximately $1.4 million in the second quarter of the previous year. These amounts mainly reflect the financial results of Lavie Bio and expenses related to the development and maintenance of MicroBoost AI for ag, which are presented as a single line item in the consolidated statement of profit and loss. This accounting treatment follows the intention to sell the majority of Lavie Bio's activities and the MicroBoost AI for ag as of June 30, 2025. All prior periods' amounts were reclassified to conform to this presentation.

Speaker #3: These amounts mainly reflect the financial results of Laviv Bio and expenses related to the development and maintenance of MicroBoost AI for Ad, which are presented as a single line item in the consolidated statements of profit and loss.

Speaker #3: This accounting treatment follows the intention to sell the majority of Laviv Bio's activities and the MicroBoost AI for Ad as of June 30, 2025.

Speaker #3: All prior period amounts were reclassified to conform to this presentation. The net loss for the first half of 2025 was approximately $7.7 million, compared to approximately $9.8 million in the same period last year.

Speaker #3: The $2.1 million decrease in net loss was primarily due to decreased operating expenses and increased financing income, net. This was partially offset by the increased loss from operations held for sale, net, and reduced revenues.

Yaron Eldad: The net loss for the first half of 2025 was approximately $7.7 million compared to approximately $9.8 million in the same period last year. The $2.1 million decrease in net loss was primarily due to decreased operating expenses and increased financing income net, partially offset by the increased loss from operations held for sales net and reduced revenues. The net loss for the second quarter of 2025 was approximately $4.7 million compared to approximately $6 million in the same period last year. The $1.3 million decrease in net loss was primarily due to decreased operating expenses, decreased loss from operations held for sale, and increased revenues partially offset by increased financing expenses, as mentioned above.

Speaker #3: The net loss for the second quarter of 2025 was approximately $4.7 million, compared to approximately $6 million in the same period last year.

Speaker #3: The $1.3 million increase in net loss was primarily due to decreased operating expenses, decreased loss from operations held for sale, and increased revenues, partially offset by increased financing expenses, as mentioned above.

Speaker #1: Welcome to Evogen's second quarter.

Speaker #4: Thank you. Welcome to Evogene's second quarter 2025 results. Thank you. Ladies and gentlemen, at this time we will begin the question and answer session.

Speaker #4: In order to send a question, use the chat button located at the bottom of your screen. Please type your full name and company name before the question.

Moderator: Welcome to Evogene Ltd.'s second quarter 2025.

Speaker 4: Thank you. Welcome to Evogene Ltd.'s second quarter 2025 results.

Speaker #4: The first question: How much castor seed inventory do you have today, both finished and expected to be finished after the harvest? And if your current customer does not place a follow-on order, what are your plans to commercialize this inventory?

Moderator: Thank you. Ladies and gentlemen, at this time, we will begin the question and answer session. In order to send a question, use the chat button located at the bottom of your screen. Please type your full name and company name before the question. The first question: How much Casterra seed inventory do you have today, both finished and expected to be finished after the harvest? If your current customer does not place a follow-on order, what are your plans to commercialize this inventory?

Speaker #2: Hi, this is Ofer Ben. Great to hear from you. I want to disclose the specific amount of inventory we have: we have a few hundred tons of castor seed, which are ready.

Speaker #2: And we have the intention to sell those seeds to our partners. But in any event, as I mentioned in the previous call, Kastera is also focusing on using our seeds in order to grow and, through subcontractors, to grow grain and sell the grain to our partners. Because in some cases, we feel that we have a better understanding of how to utilize and grow castor in certain territories compared to what our partners are doing.

Ofer Haviv: Hi, this is Ofer Haviv. It has been great to hear from you. I will not disclose the specific amount of inventory we have, but we have a few hundreds of tons in castor seeds, which they are ready. We have the intention to sell those seeds to our partner. In any event, as I mentioned in the previous call, Casterra is also focusing on using our seeds in order to grow and then through subcontractors to grow grain and to sell the grain to our partners because in some cases we feel that we have a better understanding of how to utilize and to grow castor in certain territories compared to what our partners are doing. I do not, at least at this point in time, have a question mark on how we are going to benefit from our castor seed inventory.

Speaker #2: So I don't at this point of time, I don't have question marks on how we are going to benefit from our castor seed inventory if we through a direct sale, or we are going to use this to grow castor by ourselves and then to sell the grain.

Speaker #2: And in this area, we already conduct field trials both in Brazil and in Kenya, evaluating our growth protocols in the way that we believe the industry should grow castor.

Ofer Haviv: It could be through a direct sale or we are going to use this to grow castor by ourselves and then to sell the grain. In this area, we already conducted a pre-trial both in Brazil and in Kenya evaluating our growth protocols in the way that we believe the industry should grow castor. It looks like in Brazil we already have some initial results and it looks very, very promising. We are now waiting to see the results in Kenya to see that we are also in the right direction there as well. I hope that I addressed your question.

Speaker #2: And it looks like we, in Brazil, already have some initial results, and they look very, very promising. We are now waiting to see the results in Kenya, but we see that we are also in the right direction there as well.

Speaker #2: So I hope that the rest of your question.

Speaker #1: What steps need to occur before you can announce a castor oil business?

Speaker #2: If I understand the question correctly, so it's meaning that if we are going to enter into the oil business itself, , so at least in this stage, we are putting ourselves we are entering into the area of grain cultivation and selling grain to partners.

Speaker #2: And there is enough today, both in Africa and in Brazil, crashing oil factories that are eager to receive more and more castor grain because the demand for castor oil is still high and actually increasing.

Moderator: The next question: What steps need to occur before you can announce a Casterra business?

Ofer Haviv: If I understand the question correctly, it means that if you are going to enter into the oil fields itself, at least at this stage, we are putting ourselves, we are entering into the area of grain cultivation and selling grain to partners. There is enough today both in Africa and in Brazil, crushing oil factories that are eager to receive more and more castor grain because the demand for castor oil is still high and increasing actually. The bottleneck today is really in the castor cultivation. We believe that our variety with their uniqueness and the way that we want to use them as part of our growth protocols are going to address the demand in a very, very competitive expenses and cost to grow the castor itself.

Speaker #2: So the bottleneck today is really in the castor cultivation, and we believe that our variety, with their uniqueness and the way that we want to use them as part of our growth protocol, are going to address the demand in a very, very competitive expense cost to grow the castor itself.

Speaker #2: So I think that this is what, as a shareholder, you should wait to hear from us on the results coming from our commercial field trials in growing castor for grain using our seed variety.

Speaker #1: The stock is still low. When will it start going up?

Speaker #2: This is an interesting question. You know, we never control the stock market, but what I can say is that we are now at the end of a very at the end of a long process of analyzing our strategy which we presented today.

Ofer Haviv: I think that this is what I showed that you should wait to hear from us on the results coming from our commercial field trials in growing the castor for grain using our seed variety.

Speaker #2: I hope in a very clear way. We are now in the process of finalizing a new company presentation that we are also going to have a new website that will reflect the new strategy.

Moderator: The next question: The stock is still low. When will it start going up?

Ofer Haviv: This is an interesting question. You know, you can never control the stock market, but what I can say is that we are now at the end of a very long process of analyzing our strategy, which we presented today, I hope, in a very clear way. We are now in the process of finalizing a new company presentation. We are also going to add a new website that will reflect the new strategy. We are planning to launch a feedback presentation during September and then other communication tools through the end of the year. I am planning to start to meet these investors and pitch the new company strategy. Most important, when do we start to announce a new collaboration agreement both in pharma and also in agri-tech that will strengthen the value proposition of our business model and our technology?

Speaker #2: And we are planning to launch at least one presentation during September and then other communication tools through the end of the year. I'm planning to start meeting with investors and pitch the new company strategy.

Speaker #2: And most important, most important, when they start to announce a new collaboration agreement both in the pharma and also in ad, that will strengthen the value proposition of our business model and our technology, I believe the share will start to react to this announcement.

Speaker #2: So I am quite positive about the new avenue the company is focusing on. The board is standing behind management, and I believe that together we will start to see, and I hope and believe that the capital market will start to react to the company and new strategy, and the achievements ahead of us.

Ofer Haviv: I believe the sale will start to react to this announcement. So I am quite positive about the new avenue the company is focusing on. The board is standing behind management. I believe that together I am expecting to start to see, and I hope and believe that the capital market will start to react to the company and new strategy and the achievements ahead of us.

Speaker #1: The next question: How representative are operating expenses in Q2 2025 or going forward operations? Are all cost reductions fully reflected in the numbers?

Speaker #2: So the answer is yes, and actually what we expected to see in the third and the fourth quarter. We are expecting to see a continued decline in the company expenses.

Speaker #2: I believe in all different expense items: R&D, business development, marketing itself, and also in G&A. So, actually, we are even expecting to see a continued reduction in our expenses.

Moderator: The next question: How representative are operating expenses in Q2 2025 or going forward operations? Are all cost reductions fully reflected in the numbers?

Speaker #1: What was revenue in Q2 2025? How should we think about peak sales, given recent results? And how long should it take to reach peak sales?

Ofer Haviv: The answer is yes. Actually, what we expected to see in the third and the fourth quarter, we are expecting to see a continual decline in the company expenses, I believe, in all different expense items: R&D, business development, marketing, and sales, and also in the G&A. So actually, we are even expecting to see a continual reduction in our expenses.

Speaker #2: So, I think that we are now, and we are when we're talking about sales. This specific word is relevant for Kastera because Kastera is currently our only activity that produces sales on a regular basis. The other two areas of activity, ad and pharma, which are reliant on our campus technology, will be more the collaboration tax of agreements that will include R&D fees, milestones, and royalties.

Moderator: The next question: What was revenue in Q2 2025? How should we think about peak sales given recent results? How long should it take to reach peak sales?

Ofer Haviv: I think that we are now, when I talk about sales, this specific board is relevant for Casterra because Casterra is currently our only activity that produces sales on a regular basis. There are other two areas of activity, AgPlenus and pharma, which are relying on our Kempas AI technology. It will be more collaboration type of agreements, which will include R&D fee, milestone, and royalty. When you talk about sales, it is probably preferred to Casterra, which is selling seeds. In the future, we are expecting also to sell grain.

Speaker #2: But when you talk about sales, it's probably referring to Kastera activity, which is selling seeds. In the future, we expect to sell grain as well.

Speaker #2: So, I think that what we are now doing in Kastera is talking with a few mega partners—not one, more than one—which show interest in expanding their activity in castor oil.

Speaker #2: They are all looking for ways to solve what we believe is the main challenge in the castor industry: the cost to grow the grain that you are using as the source for the oil.

Speaker #2: I think here this is the main limitation. And we believe that our variety and the growth protocol we develop which is the target is to maximize yield versus expenses, not just to maximize yield but maximize yield versus expenses.

Ofer Haviv: I think that what we are now doing in Casterra is talking with a few major partners, not one, more than one, which show interest to expand their activity in castor oil. They are all looking for ways to solve what we believe is the main challenge in the castor industry: the cost to grow the grain that you are using them as the source for the oil. I think here this is the main limitation. We believe that our variety and the growth protocol that we developed, which is in the target, is to maximize yield versus expenses, not just to maximize yield, but yield versus expenses. This is the right approach. We are now in a quite advanced stage in validating this concept both in Brazil and in Africa.

Speaker #2: This is the right approach. We are now in quite an advanced stage in validating these concepts both in Brazil and in Africa. I think that the initial indications we receive, at least at this stage in Brazil, show that there are a lot of field trials creating a lot of interest.

Speaker #2: And I hope that we will be able to disclose more information during the next quarter.

Speaker #1: The next question: For campus AI platform, what catalyst milestones should we expect in the next 12 to 18 months to evaluate progress?

Speaker #2: So, Campus AI, this is the text engine that both our divisions are using: the pharma division and the ad division. So, I can think about a few types of catalysts.

Ofer Haviv: I think that from the initial indication that we received, at least in this stage in Brazil, there is a lot of interest in the field trials. We have a lot of interest. I hope that we will be able to disclose more information during the next call.

Speaker #2: One, which is to come from the pharma or from the ad, is an announcement press release on a new collaboration with partners that are interested in getting the benefit from the campus AI, meaning that they would like to have a direct candidate targeting their protein of interest.

Moderator: The next question: For Kempas AI platform, what catalyst milestones should we expect in the next 12 to 18 months to evaluate progress?

Ofer Haviv: Kempas AI, this is the test engine that both our divisions are using: the pharma division and the agri division. I can think about two types of catalysts. One, which is to come from the pharma or from the agri. This is an announcement, references on a new collaboration with the partners that are interested in getting the benefit from Kempas AI, meaning that they would like to have a drug candidate part of their profiling of interest. They would like to benefit from Kempas AI or a strategic collaboration between AgPlenus or a strategic focusing on crop protection with companies such as Bayer, Corteva, Syngenta, and others. Bear in mind that currently we already have two strategic collaborations, one with Bayer and one with Corteva that AgPlenus is already engaged in.

Speaker #2: And they would like, you know, to benefit from campus AI or strategic collaboration between ad plans or strategically focusing on crop protection, with companies such as Bayer, Corteva, BASF, Syngenta, FMC, and others.

Speaker #2: Bear in mind that, you know, currently we already have two strategic collaborations: one with Bayer and one with Corteva. That I cannot already engage in.

Speaker #2: So this is the type of type one of press releases that you that we might release during next year announcing more and more collaborations which demonstrate the value of our technology, campus AI.

Speaker #2: In addition, we continue to invest to develop Campus AI, the engine itself. And we are doing this in some cases together with partners such as Google, as we announced in May of this year.

Speaker #2: May or June of this year. We are now in discussions with major tech companies, and we are exploring different opportunities to continue the development of our tech engine together with them.

Ofer Haviv: This is the type one of references that we might release during the next year, announcing more and more collaborations, which demonstrate the value of our technology, Kempas AI. In addition, we continue to invest to develop Kempas AI, the engine itself. We are doing it in some cases together with partners such as Google that we announced in May this year, May or June this year. We are now talking with big tech companies, and we have a strong given opportunity to continue the development of our tech engine together with them. This is another type of announcement that can come when we disclose new capabilities, breakthrough capabilities that we succeed to develop as part from our Kempas AI generative engine. We are very, very proud to announce our foundation model that was developed together with Google during the first half of this year.

Speaker #2: And this is another type of announcement that can come when we disclose new breakthrough capabilities that we have succeeded in developing as part of our campus AI generative engine.

Speaker #2: And we are very, very proud to announce our foundation model that was developed together with Google during the first half of this year.

Speaker #2: And we already see the positive effects that we have in this that this development give us in the ongoing discussion we are conducting with potential partners both in the pharma and in the ad as well.

Speaker #1: There are no further questions at this time. Mr. Haviv, would you like to make your concluding statement?

Speaker #2: Yes, thank you. I would like to thank you for taking the time to participate in this conversation, and I hope to see you all at our next meeting.

Speaker #2: Once again, thank you all.

Ofer Haviv: We already see the positive effects that we have in this development give us in the ongoing discussion we are conducting with potential partners both in the pharma and in the agri as well.

Moderator: There are no further questions at this time. Mr. Haviv, would you like to make your concluding statement?

Ofer Haviv: Yes, thank you. I would like to thank you for taking the time to participate in this conversation. I hope to see you all at our next meeting. Once again, thank you all.

Moderator: Thank you. This concludes Evogene Ltd.'s second quarter 2025 results conference call. Thank you for your participation. You may go ahead and disclose.